Chronic hepatitis B: Treatment alert

Ting-Tsung Chang, Hua Zhuang, Jidong Jia, Nancy Wai Yee Leung, Richard Guan, S. M.Wasim Jafri, Laurentius A. Lesmana, Yun Fan Liaw, Stephen Locarnini, Masao Omata, Jose D. Sollano, Dong Jin Suh, Varocha Mahachai, Pham Hoang Phiet, Shiv K. Sarin, Guangbi Yao, Seung Kew Yoon

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Chronic hepatitis B (CHB) is a serious global health concern, particularly in the Asia-Pacific region. New information on the clinical management of CHB is emerging rapidly, requiring that physicians be alerted to updated treatment recommendations. The ACT-HBV Asia-Pacific Steering Committee members, composed of experts in hepatitis B from throughout the Asia-Pacific region, reviewed and discussed new clinical data as reported in the literature or presented at recent international congresses, and recommended that physicians be alerted to updated treatment recommendations. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA levels of ≥20000IU/ml (≥105 copies/ml) and elevated alanine aminotransferase levels should be considered for treatment. It is suggested that HBV DNA≥2000IU/ml (≥104 copies/ml) is the more appropriate threshold for the treatment of HBeAg-negative patients. Lamivudine, adefovir dipivoxil, interferon α-2b, thymosin α-1, and, most recently, entecavir, and pegylated interferon α-2a are licensed for the management of CHB. The treatment recommendations from the 2005 Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B have been updated to incorporate these new therapeutic options. A summary of treatment recommendations for special patient populations is also included.

Original languageEnglish
Pages (from-to)47-58
Number of pages12
JournalLiver International
Volume26
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2006 Dec 1

Fingerprint

Chronic Hepatitis B
Hepatitis B e Antigens
Interferons
Therapeutics
Committee Membership
Thymosin
Physicians
Lamivudine
Hepatitis B
Alanine Transaminase
DNA
Population

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Chang, T-T., Zhuang, H., Jia, J., Leung, N. W. Y., Guan, R., Jafri, S. M. W., ... Yoon, S. K. (2006). Chronic hepatitis B: Treatment alert. Liver International, 26(SUPPL. 2), 47-58. https://doi.org/10.1111/j.1478-3231.2006.01374.x
Chang, Ting-Tsung ; Zhuang, Hua ; Jia, Jidong ; Leung, Nancy Wai Yee ; Guan, Richard ; Jafri, S. M.Wasim ; Lesmana, Laurentius A. ; Liaw, Yun Fan ; Locarnini, Stephen ; Omata, Masao ; Sollano, Jose D. ; Suh, Dong Jin ; Mahachai, Varocha ; Phiet, Pham Hoang ; Sarin, Shiv K. ; Yao, Guangbi ; Yoon, Seung Kew. / Chronic hepatitis B : Treatment alert. In: Liver International. 2006 ; Vol. 26, No. SUPPL. 2. pp. 47-58.
@article{8469c4a1299e42fea43940d2c27e3827,
title = "Chronic hepatitis B: Treatment alert",
abstract = "Chronic hepatitis B (CHB) is a serious global health concern, particularly in the Asia-Pacific region. New information on the clinical management of CHB is emerging rapidly, requiring that physicians be alerted to updated treatment recommendations. The ACT-HBV Asia-Pacific Steering Committee members, composed of experts in hepatitis B from throughout the Asia-Pacific region, reviewed and discussed new clinical data as reported in the literature or presented at recent international congresses, and recommended that physicians be alerted to updated treatment recommendations. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA levels of ≥20000IU/ml (≥105 copies/ml) and elevated alanine aminotransferase levels should be considered for treatment. It is suggested that HBV DNA≥2000IU/ml (≥104 copies/ml) is the more appropriate threshold for the treatment of HBeAg-negative patients. Lamivudine, adefovir dipivoxil, interferon α-2b, thymosin α-1, and, most recently, entecavir, and pegylated interferon α-2a are licensed for the management of CHB. The treatment recommendations from the 2005 Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B have been updated to incorporate these new therapeutic options. A summary of treatment recommendations for special patient populations is also included.",
author = "Ting-Tsung Chang and Hua Zhuang and Jidong Jia and Leung, {Nancy Wai Yee} and Richard Guan and Jafri, {S. M.Wasim} and Lesmana, {Laurentius A.} and Liaw, {Yun Fan} and Stephen Locarnini and Masao Omata and Sollano, {Jose D.} and Suh, {Dong Jin} and Varocha Mahachai and Phiet, {Pham Hoang} and Sarin, {Shiv K.} and Guangbi Yao and Yoon, {Seung Kew}",
year = "2006",
month = "12",
day = "1",
doi = "10.1111/j.1478-3231.2006.01374.x",
language = "English",
volume = "26",
pages = "47--58",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "SUPPL. 2",

}

Chang, T-T, Zhuang, H, Jia, J, Leung, NWY, Guan, R, Jafri, SMW, Lesmana, LA, Liaw, YF, Locarnini, S, Omata, M, Sollano, JD, Suh, DJ, Mahachai, V, Phiet, PH, Sarin, SK, Yao, G & Yoon, SK 2006, 'Chronic hepatitis B: Treatment alert', Liver International, vol. 26, no. SUPPL. 2, pp. 47-58. https://doi.org/10.1111/j.1478-3231.2006.01374.x

Chronic hepatitis B : Treatment alert. / Chang, Ting-Tsung; Zhuang, Hua; Jia, Jidong; Leung, Nancy Wai Yee; Guan, Richard; Jafri, S. M.Wasim; Lesmana, Laurentius A.; Liaw, Yun Fan; Locarnini, Stephen; Omata, Masao; Sollano, Jose D.; Suh, Dong Jin; Mahachai, Varocha; Phiet, Pham Hoang; Sarin, Shiv K.; Yao, Guangbi; Yoon, Seung Kew.

In: Liver International, Vol. 26, No. SUPPL. 2, 01.12.2006, p. 47-58.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Chronic hepatitis B

T2 - Treatment alert

AU - Chang, Ting-Tsung

AU - Zhuang, Hua

AU - Jia, Jidong

AU - Leung, Nancy Wai Yee

AU - Guan, Richard

AU - Jafri, S. M.Wasim

AU - Lesmana, Laurentius A.

AU - Liaw, Yun Fan

AU - Locarnini, Stephen

AU - Omata, Masao

AU - Sollano, Jose D.

AU - Suh, Dong Jin

AU - Mahachai, Varocha

AU - Phiet, Pham Hoang

AU - Sarin, Shiv K.

AU - Yao, Guangbi

AU - Yoon, Seung Kew

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Chronic hepatitis B (CHB) is a serious global health concern, particularly in the Asia-Pacific region. New information on the clinical management of CHB is emerging rapidly, requiring that physicians be alerted to updated treatment recommendations. The ACT-HBV Asia-Pacific Steering Committee members, composed of experts in hepatitis B from throughout the Asia-Pacific region, reviewed and discussed new clinical data as reported in the literature or presented at recent international congresses, and recommended that physicians be alerted to updated treatment recommendations. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA levels of ≥20000IU/ml (≥105 copies/ml) and elevated alanine aminotransferase levels should be considered for treatment. It is suggested that HBV DNA≥2000IU/ml (≥104 copies/ml) is the more appropriate threshold for the treatment of HBeAg-negative patients. Lamivudine, adefovir dipivoxil, interferon α-2b, thymosin α-1, and, most recently, entecavir, and pegylated interferon α-2a are licensed for the management of CHB. The treatment recommendations from the 2005 Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B have been updated to incorporate these new therapeutic options. A summary of treatment recommendations for special patient populations is also included.

AB - Chronic hepatitis B (CHB) is a serious global health concern, particularly in the Asia-Pacific region. New information on the clinical management of CHB is emerging rapidly, requiring that physicians be alerted to updated treatment recommendations. The ACT-HBV Asia-Pacific Steering Committee members, composed of experts in hepatitis B from throughout the Asia-Pacific region, reviewed and discussed new clinical data as reported in the literature or presented at recent international congresses, and recommended that physicians be alerted to updated treatment recommendations. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA levels of ≥20000IU/ml (≥105 copies/ml) and elevated alanine aminotransferase levels should be considered for treatment. It is suggested that HBV DNA≥2000IU/ml (≥104 copies/ml) is the more appropriate threshold for the treatment of HBeAg-negative patients. Lamivudine, adefovir dipivoxil, interferon α-2b, thymosin α-1, and, most recently, entecavir, and pegylated interferon α-2a are licensed for the management of CHB. The treatment recommendations from the 2005 Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B have been updated to incorporate these new therapeutic options. A summary of treatment recommendations for special patient populations is also included.

UR - http://www.scopus.com/inward/record.url?scp=33750701423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750701423&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2006.01374.x

DO - 10.1111/j.1478-3231.2006.01374.x

M3 - Review article

AN - SCOPUS:33750701423

VL - 26

SP - 47

EP - 58

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - SUPPL. 2

ER -

Chang T-T, Zhuang H, Jia J, Leung NWY, Guan R, Jafri SMW et al. Chronic hepatitis B: Treatment alert. Liver International. 2006 Dec 1;26(SUPPL. 2):47-58. https://doi.org/10.1111/j.1478-3231.2006.01374.x